TC
IOVA icon

TFS Capital’s Iovance Biotherapeutics IOVA Stock Holding History

TFS Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-11,605
Closed -$67K – 814
2015
Q3 		$67K Sell
11,605
-2,509
-18% -$19.5K 0.01% 830
2015
Q2 		$129K Buy
14,114
+1,566
+12% +$17.5K 0.01% 792
2015
Q1 		$152K Buy
+12,548
New +$141K 0.01% 821

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TFS Capital's IOVA Position: Q4 2015 in Review

TFS Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2015, closing a stake of 11,605 shares — an estimated $67K sold.

TFS Capital first reported a position in IOVA in Q1 2015 and held it in 3 quarters. The position peaked at $152K in Q1 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q4 2015.

  • TFS Capital reported no remaining Iovance Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • TFS Capital sold 11,605 Iovance Biotherapeutics shares in Q4 2015, an estimated $67K.
  • TFS Capital first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 3 quarters.
  • TFS Capital's Iovance Biotherapeutics position peaked at $152K in Q1 2015.
  • 82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.